These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26484904)

  • 21. Voxel-based classification of FDG PET in dementia using inter-scanner normalization.
    Thiele F; Young S; Buchert R; Wenzel F
    Neuroimage; 2013 Aug; 77():62-9. PubMed ID: 23541799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG PET imaging in patients with pathologically verified dementia.
    Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
    J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain 18F-FDG-PET: Utility in the Diagnosis of Dementia and Epilepsy.
    Lotan E; Friedman KP; Davidson T; Shepherd TM
    Isr Med Assoc J; 2020 Mar; 22(3):178-184. PubMed ID: 32147984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
    Koeppe RA; Gilman S; Joshi A; Liu S; Little R; Junck L; Heumann M; Frey KA; Albin RL
    J Nucl Med; 2005 Jun; 46(6):936-44. PubMed ID: 15937303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain PET in suspected dementia: patterns of altered FDG metabolism.
    Brown RK; Bohnen NI; Wong KK; Minoshima S; Frey KA
    Radiographics; 2014; 34(3):684-701. PubMed ID: 24819789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Status of
    Sarikaya I; Sarikaya A; Elgazzar AH
    J Nucl Med Technol; 2018 Dec; 46(4):362-367. PubMed ID: 30076253
    [No Abstract]   [Full Text] [Related]  

  • 28. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia.
    Kerklaan BJ; van Berckel BN; Herholz K; Dols A; van der Flier WM; Scheltens P; Pijnenburg YA
    Am J Alzheimers Dis Other Demen; 2014 Nov; 29(7):607-13. PubMed ID: 24576796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Performance of Positron Emission Tomography for the Presurgical Evaluation of Patients with Non-lesional Intractable Partial Epilepsy: Comparison among 18F-FDG, 11C-Flumazenil, and 11C-Flumazenil Binding Potential Imaging Using Statistical Imaging Analysis.
    Komoto D; Iida K; Higaki T; Kaichi Y; Takauchi K; Arihiro K; Kakita A; Hirokawa Y; Awai K
    Hiroshima J Med Sci; 2015 Dec; 64(4):51-7. PubMed ID: 26964154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
    Silverman DH
    J Nucl Med; 2004 Apr; 45(4):594-607. PubMed ID: 15073255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontal network syndrome testing: clinical tests and positron emission tomography brain imaging help distinguish the 3 most common dementia subtypes.
    Hoffmann M
    Am J Alzheimers Dis Other Demen; 2013 Aug; 28(5):477-84. PubMed ID: 23677732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature.
    Bohnen NI; Djang DS; Herholz K; Anzai Y; Minoshima S
    J Nucl Med; 2012 Jan; 53(1):59-71. PubMed ID: 22173840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.
    Jeong Y; Cho SS; Park JM; Kang SJ; Lee JS; Kang E; Na DL; Kim SE
    J Nucl Med; 2005 Feb; 46(2):233-9. PubMed ID: 15695781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.
    Foster NL; Wang AY; Tasdizen T; Fletcher PT; Hoffman JM; Koeppe RA
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S29-36. PubMed ID: 18631997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography diagnosis of Alzheimer's disease.
    Coleman RE
    Neuroimaging Clin N Am; 2005 Nov; 15(4):837-46, x. PubMed ID: 16443494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease.
    Pilotto A; Premi E; Paola Caminiti S; Presotto L; Turrone R; Alberici A; Paghera B; Borroni B; Padovani A; Perani D
    Neurology; 2018 Mar; 90(12):e1029-e1037. PubMed ID: 29453242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.